Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer

August 16, 2022

The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

August 12, 2022

The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

August 11, 2022

The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity.